Product Overview
CJC-1295 (with DAC) is a peptide supplied for commercial sourcing, research applications, and formulation development. Atlas BioLabs provides structured sourcing support with documentation, batch transparency, and scalable supply options for CJC-1295 (with DAC) peptide buyers.
CJC-1295 (with DAC) is a long-acting growth hormone releasing hormone analog used in research settings focused on endocrine signaling and peptide pharmacokinetic design. Atlas BioLabs lists CJC-1295 (with DAC) within the Metabolic Peptides category so buyers can compare product role, supply format, pricing entry points, and documentation requirements in one place.
Across technical literature, peptide research discussions, formulation-development planning, and category-level sourcing reviews, CJC-1295 (with DAC) is commonly evaluated in contexts such as endocrine pathway research, long-acting peptide design studies, experimental peptide programs. We surface that context here so buyers can understand how the peptide is usually positioned inside health-adjacent, cosmetic, signaling, metabolic, or repair-focused discussions before they move into sampling, formulation review, or quote discussions.
This peptide is studied for interaction with growth hormone releasing hormone receptor pathways, while the DAC modification is used to extend circulation time in experimental systems.
Teams reviewing this SKU often compare gHRH analog, endocrine signaling research peptide, extended-circulation model alongside factors such as dAC-modified structure, long-acting research format, high-interest peptide model when building formulation-development, sourcing, validation, and repeat-order shortlists for more serious technical, wellness-adjacent, and commercially credible peptide portfolios.